Current and emerging immunotherapeutic approaches for biliary tract cancers
Authors:
- 7 September 2022
- journal article
- review article
- Published by Elsevier in Hepatobiliary & Pancreatic Diseases International
- Vol. 21 (5) , 440-449
Abstract
No abstract availableKeywords
This publication has 85 references indexed in Scilit:
- Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancersProtein & Cell, 2017
- A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancerCancer Science, 2017
- Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic CholangiocarcinomaAnnals of Surgical Oncology, 2016
- Genomic spectra of biliary tract cancerNature Genetics, 2015
- Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancerInvestigational New Drugs, 2014
- Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial CancerScience, 2014
- Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract CancerJournal of Gastrointestinal Surgery, 2013
- Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract CancerClinical Cancer Research, 2013
- Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract CancerJournal of Immunotherapy, 2011
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010